Humana Inc.
HUM - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$49.77B
Close$
Earnings Call Q2 2026
July 29, 2026 - AI Summary
2026 performance & near-term outlook (costs, margin, execution): Management said year-to-date performance is “in line with expectations” and remains on track to double individual Medicare Advantage (MA) pretax margin in 2026 (excluding Stars headwind). They guided full-year 2026 medical+pharmacy cost trend to ~7%–8%, noting slight favorability in inpatient. Operationally, the 2Q consolidated operating cost ratio fell 120 bps YoY, with an expectation of ~150 bps full-year improvement—attributed to their transformation/operating model initiatives.
2027 MA bid posture & path to 2028 margin target: Their #1 priority in 2027 bids is margin progression to support a commitment of returning to a sustainable MA pretax margin of at least ~3% in 2028. They expect meaningful progress in 2027, but did not provide bid-specific numeric margin bridge guidance, emphasizing that ultimate results depend on final 2027 membership size/composition. They highlighted that drug trend remains high and is expected to tick modestly higher in 2027, and that they build contingency because bids are set ~6 months ahead and markets can move.
Plan exits (estimated impact) and membership/benefits tradeoffs: For 2027, they expect plan exits impacting ~600,000 members, similar in concept to prior years’ approach, and said they will prioritize higher-performing plans (including those with more value-based care penetration) to reduce disruption and recapture a significant portion of exited members (citing they did so in 2025). They framed this less as a Stars tactic and more as portfolio underwriting margin + capital return optimization.
Exclusive for Stockcircle Pro members
Sign up
$468.17
12.2% upside
Current Fair Value
12.2% upsideUndervalued by 12.2% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $49.77 Billion |
|---|---|
| Enterprise Value | $57.38 Billion |
| Annual dividend | $3.54 |
| Dividend yield | 0.85% |
| Earnings per Share | $9.87 |
| Beta | 0.74 |
| Outstanding Shares | 120,199,000 |
Return
| Return on Equity | 6.65% |
|---|---|
| Return on Assets | 2.23% |
| Return on Invested Capital | 6.59% |
Valuation & Multiples
| P/E Ratio | 38.92 |
|---|---|
| PEG | 143.32 |
| Price to Sales | 0.34 |
| Price to Book Ratio | 2.61 |
| Enterprise Value to Revenue | 0.39 |
| Enterprise Value to EBIT | 25.46 |
| Enterprise Value to Net Income | 44 |
| Total Debt to Enterprise | 0.25 |
| Debt to Equity | 0.75 |
Revenue Sources
No data
Last Earnings Call
Report Date
November 4, 2026
EPS Estimate
$-1.03
Consensus analyst estimateRevenue Estimate
$40.87 B
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.0000▼ 88.24% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 6.07%▼ 93.47% |
|---|---|
| Total Invested | $2.79B▼ 94.16% |
| Investors Holding | 319▼ 675.00% |
About Humana Inc.
67,060 employees
CEO: Bruce Broussard
Humana Inc., along with its various subsidiaries, functions as a prominent health and well-being organization exclusively within the United States. Its operations are strategically divided into three key divisions: Retail, Group and Spec...